Olema Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
Filed June 8, 2021, with a signature dated June 9, 2021. The filing reports results of Olema Pharmaceuticals’ 2021 annual meeting of stockholders, held virtually on June 8, 2021. The company’s common stock trades on the Nasdaq Global Select Market under the symbol OLMA.
Holders of 29,279,542 shares, representing 72.9% of the 40,169,738 shares outstanding as of the April 21, 2021 record date, were present virtually or by proxy, constituting a quorum.
Key Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial performance metrics.
Material Changes Versus the Prior Comparable Period
No financial or operating comparison with a prior period is included. The material developments reported are the election of three Class I directors and ratification of the independent registered public accounting firm.
Meeting Results, Outlook, and Risks
| Proposal | Result | Voting Results |
|---|---|---|
| Election of Class I directors | All three nominees elected to serve until the 2024 annual meeting or until successors are elected and qualified. | Ian Clark: 25,587,525 for, 2,915,583 withheld, 776,434 broker non-votes; Sandra Horning, M.D.: 28,476,444 for, 26,664 withheld, 776,434 broker non-votes; Gorjan Hrustanovic, Ph.D.: 25,690,868 for, 2,812,240 withheld, 776,434 broker non-votes. |
| Ratification of Ernst & Young LLP | Approved for the fiscal year ending December 31, 2021. | 29,279,502 for, 22 against, and 18 abstentions. |
The filing contains no management guidance, business outlook, contingencies, or specific risk disclosures. It does not report unusual financial items or changes in capital structure.
Important Facts to Verify
- Confirm the composition and terms of the Class I director appointments through the company’s proxy materials.
- Verify Ernst & Young LLP’s appointment as independent registered public accounting firm for fiscal 2021.
- Review the company’s periodic financial filings for revenue, cash position, operating expenses, cash runway, debt, and clinical-development updates, none of which are provided in this 8-K.
- Note that broker non-votes affected the director elections but were not applicable to the auditor ratification vote.